What is the recommended management of ethambutol-induced toxicity in a patient receiving anti‑tuberculosis therapy?

Management of Ethambutol Toxicity

Stop ethambutol immediately and permanently at the first sign of any visual symptom—decreased acuity, color vision loss, or scotomata—because the toxicity may be irreversible and rechallenge is contraindicated. 1

Immediate Actions Upon Suspected Toxicity

• Discontinue ethambutol at once when the patient reports blurred vision, difficulty distinguishing colors (especially red-green), visual field defects, or any other visual change 1
• Never rechallenge with ethambutol after documented optic toxicity, as this can lead to permanent visual impairment 2
• If the patient is also receiving linezolid (common in drug-resistant TB), stop both agents immediately; linezolid may be cautiously reintroduced after vision normalizes, but ethambutol must remain permanently discontinued 2

Diagnostic Confirmation

• Perform Snellen chart visual acuity testing to document the degree of impairment 2
• Conduct red-green color discrimination testing using Ishihara plates or formal color vision assessment, as this is a hallmark finding of ethambutol-induced optic neuropathy 3, 2
• Assess visual fields through finger perimetry or formal perimetry to detect central or cecocentral scotomata 2
• Recognize that ethambutol toxicity presents as optic or retrobulbar neuritis and is dose-dependent, with risk increasing at doses >15 mg/kg/day or treatment duration >2 months 2

Regimen Modification After Discontinuation

Replace ethambutol with an alternative anti-TB drug to maintain at least four effective agents in the initial phase or three in the continuation phase:

• First-line replacement: Add a fluoroquinolone (moxifloxacin 400 mg daily or levofloxacin) when the M. tuberculosis isolate is drug-susceptible 2
• Alternative replacement: Use streptomycin if renal function permits, with appropriate renal monitoring and dose adjustment 1
• For rifampin-resistant or MDR-TB: Ensure the regimen includes Group A drugs such as bedaquiline, linezolid, and a fluoroquinolone 2
• If ethambutol must be omitted from a standard regimen and pyrazinamide was not used or cannot be tolerated, extend total treatment duration to 9 months 1

Prognosis and Reversibility

• Ethambutol-induced optic toxicity is generally reversible if detected promptly and the drug is stopped immediately 2, 4
• Maximum visual recovery typically occurs within the first 6–8 weeks after discontinuation, though complete recovery is not guaranteed 4
• Delayed recognition or continued use despite symptoms can result in permanent, irreversible visual impairment 2, 5, 6

Prevention: Baseline Screening and Monitoring

Before Starting Ethambutol

• Test visual acuity using a Snellen chart and document that the patient can appreciate and report visual changes 1
• Verify renal function before prescribing ethambutol; avoid the drug in renal failure or substantially reduce the dose with therapeutic drug monitoring if dialysis is used 1
• Educate the patient (and family members for young children or those with communication barriers) to stop ethambutol immediately and report to the physician if any visual symptoms occur 1
• Inform the general practitioner of this precaution 1

During Ethambutol Therapy

• Perform monthly visual acuity and color discrimination testing for all patients, especially those receiving >15 mg/kg/day, treatment >2 months, or with renal insufficiency 2
• Actively inquire about visual disturbances (blurred vision, scotomata, color vision changes) at every visit 2
• For patients receiving 25 mg/kg/day (retreatment dosing), monthly eye examinations are mandatory 7

Special Populations and Precautions

Young Children and Communication Barriers

• Use ethambutol cautiously in small children and patients with language difficulties who cannot reliably report visual symptoms 1
• Provide education to parents or family members to observe and report any visual changes 1, 2
• Consider alternative fourth drugs (e.g., streptomycin or ethionamide) in children unable to communicate visual symptoms 8

Renal Impairment

• Ethambutol is renally excreted; avoid or substantially reduce the dose in patients with creatinine clearance <70 mL/min or end-stage renal disease 1, 2
• If ethambutol must be used in renal failure, monitor serum drug concentrations and adjust dosing accordingly 1

HIV Co-infection

• In people living with HIV with advanced immunosuppression (CD4 <50 cells/mm³), distinguish ethambutol toxicity from CMV retinitis, which presents with hemorrhagic retinal necrosis and perivascular exudates 2
• Refer promptly to an ophthalmologist for dilated fundoscopy to rule out CMV retinitis and other HIV-related ocular pathologies 2
• The tenofovir/lamivudine/dolutegravir antiretroviral regimen should not be altered solely because of ethambutol toxicity, as these drugs are not implicated and have no significant interaction with rifampin 2

Common Pitfalls to Avoid

• Do not continue ethambutol while "monitoring closely" after suspected toxicity; immediate permanent discontinuation is required 2
• Do not prescribe ethambutol to patients who cannot reliably report visual symptoms unless a caregiver can monitor for changes 1, 2
• Do not omit replacement of ethambutol without adding another effective drug, as this risks treatment failure or acquired resistance 2
• Do not overlook renal dosing adjustments; failure to reduce the dose in renal impairment markedly increases the risk of optic toxicity 1, 2
• Do not assume reversibility; although many cases improve after discontinuation, permanent visual loss can occur, particularly with delayed recognition 2, 5, 6